Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Antacid on SMC021 PK/PD in Postmenopausal Women
NCT00421590Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of calcitonin salmon in postmenopausal osteoporosis (2 arms), sponsored by Novartis. Primary endpoints: Pharmacokinetics of SMC021 and Serum C-telopeptide of type I collagen. Started Oct 2006; status: completed.
02
Drugs
calcitonin salmon
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00421590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00421590.